| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
BCN-PEG4-acid does not target a specific protein directly. Instead, its primary reactivity target is azide-functionalized molecules, enabling selective conjugation via SPAAC. In ADC applications, it links an antibody (via conjugation to lysine residues) to a cytotoxic payload, while in PROTACs, it serves as a linker connecting an E3 ligase ligand and a target protein ligand to facilitate ubiquitination and degradation of specific disease-relevant proteins.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
In vitro, BCN-PEG4-acid functions as a chemical tool for constructing bioconjugates rather than as a pharmacologically active molecule. It is used to covalently link an antibody to a cytotoxic payload through its terminal carboxylic acid and BCN groups, forming stable ADC constructs that bind to target cancer cells and deliver the cytotoxic agent intracellularly following antibody-antigen recognition. In PROTAC synthesis, the linker connects the warhead and E3 ligand, enabling the formation of bifunctional molecules that induce targeted protein degradation. |
| ln Vivo |
Direct in vivo activity of BCN-PEG4-acid itself is not reported, as it is an inert linker used solely as a chemical construction tool. However, ADCs and PROTACs synthesized using BCN-PEG4-acid exhibit in vivo efficacy in animal models. When used as a PROTAC linker, the resulting bifunctional molecule leverages the ubiquitin-proteasome system to selectively degrade target proteins in vivo. When used in ADCs, the construct enables targeted delivery of cytotoxins to tumor tissues, enhancing therapeutic index and reducing systemic toxicity.
|
| Enzyme Assay |
Experimental protocols for antibody conjugation: Dissolve BCN-PEG4-acid in DMSO to prepare a stock solution. Activate the terminal carboxylic acid with EDC/NHS in MES buffer at pH 5.5-6.0 for 15-30 min. Add the activated linker to antibody solution in PBS (pH 7.4) and incubate at room temperature for 2-4 h with gentle mixing. For click chemistry conjugation, dissolve the azide-functionalized payload in PBS, add BCN-PEG4-acid, and incubate at 25-37degC for 1-4 h. Purify conjugates by size exclusion chromatography or dialysis.
|
| Cell Assay |
For BCN-PEG4-acid linker conjugation to antibodies, first activate the linker (if required) by dissolving in DMSO to 10-20 mM. Add the activated linker to antibody solution (1-10 mg/mL in PBS, pH 7.4) at a molar ratio of 5-20:1 (linker:antibody). Incubate at 25degC for 2-4 h with gentle rotation. For click chemistry with azide-labeled cells or biomolecules, add BCN-PEG4-acid (10-100 uM final concentration) to culture media and incubate at 37degC for 1-4 h. For cytotoxicity studies, treat cells with ADC-PEG4 conjugates (0.001-100 uM) for 48-72 h and assess viability with MTT or CellTiter-Glo.
|
| Animal Protocol |
For in vivo efficacy studies of ADCs or PROTACs containing BCN-PEG4-acid as a linker, use female BALB/c nude mice (6-8 weeks, 18-22 g) bearing subcutaneous xenograft tumors. Administer the conjugate intravenously (via tail vein) or intraperitoneally at doses ranging from 1-10 mg/kg (ADC) or 10-50 mg/kg (PROTAC), typically on days 0, 3, 7, 10, or weekly. Monitor tumor volume (caliper measurements) and body weight every 2-3 days. Collect blood at multiple time points for PK analysis and harvest tumors/organs at study endpoint for biodistribution and pharmacodynamic analysis.
|
| ADME/Pharmacokinetics |
The hydrophilic PEG4 spacer enhances solubility and stability in biological fluids, which can improve absorption and reduce aggregation. The linker itself is chemically and metabolically stable under physiological conditions, with the amide bond formed via the carboxylic acid group providing stable conjugation. The BCN-azide cycloaddition product is also stable in vivo. As part of an ADC or PROTAC construct, its ADME properties are dominated by the larger conjugate molecule.
|
| Toxicity/Toxicokinetics |
BCN-PEG4-acid is not classified as a hazardous substance and is considered non-toxic at typical research concentrations. However, it should be handled with standard laboratory precautions: use PPE including gloves and goggles, avoid inhalation and skin contact. Under fire conditions, it may decompose and emit irritating fumes. The strain-promoted click reaction does not require toxic copper catalysts, enhancing biocompatibility. For large-scale synthesis, appropriate ventilation is recommended.
|
| References | |
| Additional Infomation |
BCN-PEG4-acid is exclusively a research reagent used as a building block in chemical biology. It has no direct clinical use. Its primary applications include: 1) ADC synthesis as a cleavable PEG-based linker; 2) PROTAC synthesis as a linker to join E3 ligase and target protein ligands; 3) Bioconjugation via copper-free SPAAC and amide coupling; 4) Surface and nanoparticle functionalization. It is not approved for therapeutic use. BCN reacts efficiently with electron-deficient aryl azides, making it suitable for time-sensitive live-cell and in vivo applications.
|
| Molecular Formula |
C22H35NO8
|
|---|---|
| Molecular Weight |
441.5152
|
| Exact Mass |
441.236
|
| CAS # |
1881221-47-1
|
| PubChem CID |
75412405
|
| Appearance |
Colorless to light yellow viscous liquid
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
31
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@@H]2[C@@H](C2COC(=O)NCCOCCOCCOCCOCCC(=O)O)CCC#C1
|
| InChi Key |
MOPSTLKSTPBGBX-YOFSQIOKSA-N
|
| InChi Code |
InChI=1S/C22H35NO8/c24-21(25)7-9-27-11-13-29-15-16-30-14-12-28-10-8-23-22(26)31-17-20-18-5-3-1-2-4-6-19(18)20/h18-20H,3-17H2,(H,23,26)(H,24,25)/t18-,19+,20?
|
| Chemical Name |
3-[2-[2-[2-[2-[[(1R,8S)-9-bicyclo[6.1.0]non-4-ynyl]methoxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| Synonyms |
BCNPEG4acid; BCN PEG4 acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2649 mL | 11.3245 mL | 22.6490 mL | |
| 5 mM | 0.4530 mL | 2.2649 mL | 4.5298 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
